CVE:LXG LexaGene (LXG) Stock Price, News & Analysis C$0.10 -0.03 (-19.23%) As of 02/21/2023 Add Compare Share Share Stock Analysis Stock Analysis About LexaGene Stock (CVE:LXG) Get LexaGene alerts:Sign Up Key Stats Today's RangeC$0.10▼C$0.1450-Day RangeC$0.11▼C$0.1152-Week RangeC$0.07▼C$0.31Volume2.14 million shsAverage Volume170,061 shsMarket CapitalizationC$14.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts. Read More Receive LXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LexaGene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXG Stock News HeadlinesBiosynex SA ALBIONovember 12, 2023 | morningstar.comMCyclopharm Ltd CYCOctober 31, 2023 | morningstar.comMYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.October 15 at 1:00 AM | Profits Run (Ad)Lexagene Holdings Inc (LXGh)October 16, 2023 | investing.comEurobio Scientific Bearer and/or Registered shares issued from reverse spliSeptember 2, 2023 | morningstar.comMZhejiang Gongdong Medical Technology Co Ltd Class AJuly 28, 2023 | morningstar.comMIIROC Trading Halt - LXGFebruary 22, 2023 | finance.yahoo.comLexaGene Says Large Biopharma Co Engages It in Statement of Work to Expedite Technology Validation - Marketscreener.comOctober 20, 2022 | marketscreener.comMSee More Headlines LXG Stock Analysis - Frequently Asked Questions How have LXG shares performed this year? LexaGene's stock was trading at C$0.11 at the beginning of 2026. Since then, LXG shares have increased by 0.0% and is now trading at C$0.11. What other stocks do shareholders of LexaGene own? Based on aggregate information from My MarketBeat watchlists, some other companies that LexaGene investors own include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Inovio Pharmaceuticals (INO), WELL Health Technologies (WELL), Alibaba Group (BABA), Berkshire Hathaway (BRK.B) and Ericsson (ERIC). Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolCVE:LXG CIKN/A Webwww.lexagene.com Phone800-215-1824FaxN/AEmployees41Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$8.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-339.54% Return on Assets-120.21% Debt Debt-to-Equity Ratio138.01 Current Ratio1.39 Quick Ratio1.13 Sales & Book Value Annual SalesC$110.93 thousand Price / Sales133.13 Cash FlowC$0.00 per share Price / Cash Flow21.25 Book ValueC$0.01 per share Price / Book10.50Miscellaneous Outstanding Shares140,640,000Free FloatN/AMarket CapC$14.77 million OptionableNot Optionable Beta2.26 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (CVE:LXG) was last updated on 2/21/2023 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LexaGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LexaGene With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
